Schrödinger, a provider of a computational platform used to accelerate drug discovery and materials design, revealed on Friday that it has received a milestone payment from Ono Pharmaceutical Co Ltd.
Ono has used Schrödinger's advanced computational platform to develop novel therapeutic candidates acting on its therapeutic target.
Under the programme, Schrödinger deployed its reaction-based enumeration tools and machine-learning technologies to identify and filter potential ligands for the target under the collaboration. Its physics-based computational assays were then used to predict potency with experimental accuracy. The integration of physics-based molecular simulations with machine learning enabled efficient prioritization of promising therapeutic candidates, reducing the number of compounds that had to be synthesized.
In conjunction, Schrödinger said its research collaborations with leading biotech and pharmaceutical companies around the world have already led to two FDA-approved oncology drugs and several clinical-stage assets. More than two dozen additional programmes across multiple indications are moving through discovery and development.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval